Update index.html
Browse files- index.html +244 -168
index.html
CHANGED
|
@@ -3,17 +3,24 @@
|
|
| 3 |
<head>
|
| 4 |
<meta charset="UTF-8">
|
| 5 |
<meta name="viewport" content="width=device-width, initial-scale=1.0">
|
| 6 |
-
<title>
|
| 7 |
<style>
|
| 8 |
:root {
|
| 9 |
-
--bg: #
|
| 10 |
--text: #1a1a1a;
|
| 11 |
-
--accent: #
|
| 12 |
--card-bg: #ffffff;
|
| 13 |
-
--border: #
|
| 14 |
-
--muted: #
|
| 15 |
-
--tag-bg: #
|
| 16 |
-
--tag-text: #
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 17 |
}
|
| 18 |
|
| 19 |
* {
|
|
@@ -31,81 +38,79 @@
|
|
| 31 |
}
|
| 32 |
|
| 33 |
.container {
|
| 34 |
-
max-width:
|
| 35 |
margin: 0 auto;
|
| 36 |
}
|
| 37 |
|
| 38 |
/* Header */
|
| 39 |
-
.
|
| 40 |
-
font-size: 0.
|
| 41 |
-
letter-spacing: 0.
|
| 42 |
text-transform: uppercase;
|
| 43 |
color: var(--muted);
|
| 44 |
margin-bottom: 0.25rem;
|
| 45 |
}
|
| 46 |
|
| 47 |
h1 {
|
| 48 |
-
font-size: 2.
|
| 49 |
font-weight: 400;
|
| 50 |
-
line-height: 1.2;
|
| 51 |
color: var(--accent);
|
| 52 |
-
margin-bottom: 0.25rem;
|
| 53 |
letter-spacing: -0.01em;
|
|
|
|
| 54 |
}
|
| 55 |
|
| 56 |
.subtitle {
|
| 57 |
font-size: 1rem;
|
| 58 |
font-style: italic;
|
| 59 |
color: var(--muted);
|
| 60 |
-
margin-bottom:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 61 |
border-bottom: 1px solid var(--border);
|
| 62 |
padding-bottom: 1.2rem;
|
|
|
|
|
|
|
|
|
|
|
|
|
| 63 |
}
|
| 64 |
|
| 65 |
/* Cards */
|
| 66 |
.card {
|
| 67 |
background: var(--card-bg);
|
| 68 |
border: 1px solid var(--border);
|
| 69 |
-
border-radius:
|
| 70 |
-
padding: 1.5rem;
|
| 71 |
-
margin-bottom: 1.
|
| 72 |
-
box-shadow: 0 1px 3px rgba(0,0,0,0.
|
| 73 |
}
|
| 74 |
|
| 75 |
.card h2 {
|
| 76 |
-
font-size: 1.
|
| 77 |
font-weight: 400;
|
| 78 |
color: var(--accent);
|
| 79 |
-
margin-bottom: 0.75rem;
|
| 80 |
-
letter-spacing: -0.01em;
|
| 81 |
border-bottom: 1px solid var(--border);
|
| 82 |
padding-bottom: 0.5rem;
|
|
|
|
|
|
|
| 83 |
}
|
| 84 |
|
| 85 |
.card h3 {
|
| 86 |
-
font-size:
|
| 87 |
font-weight: 700;
|
| 88 |
-
margin:
|
| 89 |
-
color:
|
| 90 |
}
|
| 91 |
|
| 92 |
-
.card p,
|
| 93 |
-
|
| 94 |
-
font-size: 0.95rem;
|
| 95 |
color: #333;
|
| 96 |
-
margin-bottom: 0.
|
| 97 |
-
}
|
| 98 |
-
|
| 99 |
-
.card ul {
|
| 100 |
-
list-style-type: "β ";
|
| 101 |
-
padding-left: 1.2rem;
|
| 102 |
}
|
| 103 |
|
| 104 |
-
|
| 105 |
-
margin-bottom: 0.35rem;
|
| 106 |
-
}
|
| 107 |
-
|
| 108 |
-
/* Table */
|
| 109 |
.table-wrap {
|
| 110 |
overflow-x: auto;
|
| 111 |
margin: 1rem 0;
|
|
@@ -114,80 +119,90 @@
|
|
| 114 |
table {
|
| 115 |
width: 100%;
|
| 116 |
border-collapse: collapse;
|
| 117 |
-
font-size: 0.
|
| 118 |
}
|
| 119 |
|
| 120 |
th {
|
| 121 |
text-align: left;
|
| 122 |
font-weight: 600;
|
| 123 |
-
font-size: 0.
|
| 124 |
-
letter-spacing: 0.
|
| 125 |
text-transform: uppercase;
|
| 126 |
color: var(--muted);
|
| 127 |
-
padding: 0.
|
| 128 |
-
border-bottom:
|
|
|
|
| 129 |
}
|
| 130 |
|
| 131 |
td {
|
| 132 |
-
padding: 0.
|
| 133 |
border-bottom: 1px solid var(--border);
|
| 134 |
vertical-align: top;
|
| 135 |
}
|
| 136 |
|
| 137 |
-
|
| 138 |
-
|
|
|
|
|
|
|
|
|
|
|
|
|
| 139 |
display: inline-block;
|
| 140 |
-
|
| 141 |
-
|
| 142 |
-
font-size: 0.75rem;
|
| 143 |
-
font-weight: 600;
|
| 144 |
letter-spacing: 0.04em;
|
| 145 |
-
padding: 0.2rem 0.
|
| 146 |
border-radius: 3px;
|
| 147 |
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 148 |
margin-bottom: 0.3rem;
|
| 149 |
}
|
| 150 |
-
|
| 151 |
-
|
| 152 |
-
|
|
|
|
| 153 |
}
|
| 154 |
|
| 155 |
-
/* Timeline */
|
| 156 |
-
.
|
| 157 |
-
|
| 158 |
-
|
| 159 |
-
margin
|
|
|
|
| 160 |
}
|
| 161 |
|
| 162 |
-
.
|
| 163 |
-
font-weight: 700;
|
| 164 |
color: var(--accent);
|
| 165 |
-
min-width: 2.2rem;
|
| 166 |
-
font-size: 0.9rem;
|
| 167 |
}
|
| 168 |
|
| 169 |
/* Footer */
|
| 170 |
footer {
|
| 171 |
text-align: center;
|
| 172 |
-
font-size: 0.
|
| 173 |
color: var(--muted);
|
| 174 |
margin-top: 2rem;
|
| 175 |
-
padding-top:
|
| 176 |
border-top: 1px solid var(--border);
|
| 177 |
}
|
| 178 |
|
| 179 |
-
@media (max-width:
|
| 180 |
-
body {
|
| 181 |
-
|
| 182 |
-
}
|
| 183 |
-
|
| 184 |
-
h1 {
|
| 185 |
-
font-size: 1.6rem;
|
| 186 |
-
}
|
| 187 |
-
|
| 188 |
-
.card {
|
| 189 |
-
padding: 1rem;
|
| 190 |
-
}
|
| 191 |
}
|
| 192 |
</style>
|
| 193 |
</head>
|
|
@@ -195,123 +210,184 @@
|
|
| 195 |
<div class="container">
|
| 196 |
|
| 197 |
<!-- Header -->
|
| 198 |
-
<div class="
|
| 199 |
-
<h1>
|
| 200 |
-
<div class="subtitle">Pro Se Disability Litigant Empowerment Foundation
|
| 201 |
-
|
| 202 |
-
|
| 203 |
-
|
| 204 |
-
<h2>1. Mission & Model</h2>
|
| 205 |
-
<p>The PSDLEF bridges the accessibility gap for pro se disability litigants by combining <strong>AI-driven legal scaffolding</strong>, neurodiversity-informed advocacy, and a self-sustaining social-impact endowment. The foundation never solicits ongoing donationsβits $300,000,000 corpus, governed by the DYREO Algorithm, permanently funds all operations.</p>
|
| 206 |
-
|
| 207 |
-
<h3>Core Services</h3>
|
| 208 |
-
<ul>
|
| 209 |
-
<li><strong>Legal Scaffolding:</strong> Automated, court-compliant generation of pleadings, writs, and petitions tailored to ADA, Section 504, and constitutional claims.</li>
|
| 210 |
-
<li><strong>Neurodiversity Advocacy:</strong> Ethical integration of polygenic risk scores and neurogenomic evidence into accommodation cases.</li>
|
| 211 |
-
<li><strong>Resource Center:</strong> Disability-inclusive court navigation tools, on-demand training modules, and a peer advocacy network.</li>
|
| 212 |
-
</ul>
|
| 213 |
-
<div class="tag-row">
|
| 214 |
-
<span class="tag">ADA Title II/III</span>
|
| 215 |
-
<span class="tag">Section 504</span>
|
| 216 |
-
<span class="tag">Constitutional Claims</span>
|
| 217 |
-
<span class="tag">PRS-Informed</span>
|
| 218 |
-
<span class="tag">Pro Se</span>
|
| 219 |
-
</div>
|
| 220 |
</div>
|
| 221 |
|
| 222 |
-
<!--
|
| 223 |
<div class="card">
|
| 224 |
-
<h2>
|
| 225 |
-
<p>The <strong>Dynamic Yield & Real Estate Optimization (DYREO) Algorithm</strong> autonomously manages the endowment across three tiers, blending financial security with mandated social utility.</p>
|
| 226 |
-
|
| 227 |
<div class="table-wrap">
|
| 228 |
<table>
|
| 229 |
<thead>
|
| 230 |
-
<tr>
|
| 231 |
-
<th>Tier</th>
|
| 232 |
-
<th>Allocation</th>
|
| 233 |
-
<th>Assets</th>
|
| 234 |
-
</tr>
|
| 235 |
</thead>
|
| 236 |
<tbody>
|
| 237 |
-
<tr>
|
| 238 |
-
|
| 239 |
-
|
| 240 |
-
|
| 241 |
-
</tr>
|
| 242 |
-
<tr>
|
| 243 |
-
|
| 244 |
-
|
| 245 |
-
|
| 246 |
-
</tr>
|
| 247 |
-
<tr>
|
| 248 |
-
<td><strong>Liquidity Reserve</strong></td>
|
| 249 |
-
<td>15% ($45M)</td>
|
| 250 |
-
<td>Money markets, short-term Treasuries β covering 3β5 years of operating expenses</td>
|
| 251 |
-
</tr>
|
| 252 |
</tbody>
|
| 253 |
</table>
|
| 254 |
</div>
|
| 255 |
-
|
| 256 |
-
<p><strong>Yield Target:</strong> 5β7% net annually, generating $15Mβ$21M for operations.<br>
|
| 257 |
-
<strong>Rebalancing:</strong> Quarterly, with strict fossil-fuel and ADA-violator exclusion screens.</p>
|
| 258 |
</div>
|
| 259 |
|
| 260 |
-
<!--
|
| 261 |
<div class="card">
|
| 262 |
-
<h2>
|
| 263 |
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 264 |
|
| 265 |
-
<h3>
|
| 266 |
-
<
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 267 |
|
| 268 |
-
<h3>
|
| 269 |
-
<
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 270 |
|
| 271 |
-
<
|
| 272 |
-
|
| 273 |
-
<
|
| 274 |
-
<
|
| 275 |
-
|
| 276 |
-
|
| 277 |
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 278 |
|
| 279 |
-
|
| 280 |
-
|
| 281 |
-
|
| 282 |
-
|
| 283 |
-
|
| 284 |
-
<li>
|
| 285 |
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 286 |
</ul>
|
| 287 |
</div>
|
| 288 |
|
| 289 |
-
<!--
|
| 290 |
<div class="card">
|
| 291 |
-
<h2>
|
| 292 |
-
<div class="
|
| 293 |
-
<
|
| 294 |
-
|
| 295 |
-
|
| 296 |
-
|
| 297 |
-
|
| 298 |
-
|
| 299 |
-
|
| 300 |
-
|
| 301 |
-
|
| 302 |
-
|
| 303 |
-
|
| 304 |
-
|
| 305 |
-
|
| 306 |
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 307 |
</div>
|
| 308 |
</div>
|
| 309 |
|
| 310 |
<!-- Footer -->
|
| 311 |
<footer>
|
| 312 |
-
<em>
|
| 313 |
<br><br>
|
| 314 |
-
© 2026 Pro Se Disability Litigant Empowerment Foundation
|
| 315 |
</footer>
|
| 316 |
|
| 317 |
</div>
|
|
|
|
| 3 |
<head>
|
| 4 |
<meta charset="UTF-8">
|
| 5 |
<meta name="viewport" content="width=device-width, initial-scale=1.0">
|
| 6 |
+
<title>MASTER INDEX β Portfolio Table of Contents | PSDLEF Technical Package</title>
|
| 7 |
<style>
|
| 8 |
:root {
|
| 9 |
+
--bg: #fafaf8;
|
| 10 |
--text: #1a1a1a;
|
| 11 |
+
--accent: #1e3a4f;
|
| 12 |
--card-bg: #ffffff;
|
| 13 |
+
--border: #d9d6ce;
|
| 14 |
+
--muted: #5a5a5a;
|
| 15 |
+
--tag-bg: #e6eef3;
|
| 16 |
+
--tag-text: #1e3a4f;
|
| 17 |
+
--flag-bg: #fff3e0;
|
| 18 |
+
--flag-text: #a15813;
|
| 19 |
+
--alert-bg: #fdecea;
|
| 20 |
+
--alert-text: #b71c1c;
|
| 21 |
+
--ok-bg: #e8f5e9;
|
| 22 |
+
--ok-text: #1b5e20;
|
| 23 |
+
--row-stripe: #fcfcf9;
|
| 24 |
}
|
| 25 |
|
| 26 |
* {
|
|
|
|
| 38 |
}
|
| 39 |
|
| 40 |
.container {
|
| 41 |
+
max-width: 960px;
|
| 42 |
margin: 0 auto;
|
| 43 |
}
|
| 44 |
|
| 45 |
/* Header */
|
| 46 |
+
.doc-id {
|
| 47 |
+
font-size: 0.8rem;
|
| 48 |
+
letter-spacing: 0.22em;
|
| 49 |
text-transform: uppercase;
|
| 50 |
color: var(--muted);
|
| 51 |
margin-bottom: 0.25rem;
|
| 52 |
}
|
| 53 |
|
| 54 |
h1 {
|
| 55 |
+
font-size: 2.2rem;
|
| 56 |
font-weight: 400;
|
|
|
|
| 57 |
color: var(--accent);
|
|
|
|
| 58 |
letter-spacing: -0.01em;
|
| 59 |
+
margin-bottom: 0.1rem;
|
| 60 |
}
|
| 61 |
|
| 62 |
.subtitle {
|
| 63 |
font-size: 1rem;
|
| 64 |
font-style: italic;
|
| 65 |
color: var(--muted);
|
| 66 |
+
margin-bottom: 0.5rem;
|
| 67 |
+
}
|
| 68 |
+
|
| 69 |
+
.version-line {
|
| 70 |
+
font-size: 0.8rem;
|
| 71 |
+
color: var(--muted);
|
| 72 |
border-bottom: 1px solid var(--border);
|
| 73 |
padding-bottom: 1.2rem;
|
| 74 |
+
margin-bottom: 2rem;
|
| 75 |
+
display: flex;
|
| 76 |
+
justify-content: space-between;
|
| 77 |
+
flex-wrap: wrap;
|
| 78 |
}
|
| 79 |
|
| 80 |
/* Cards */
|
| 81 |
.card {
|
| 82 |
background: var(--card-bg);
|
| 83 |
border: 1px solid var(--border);
|
| 84 |
+
border-radius: 5px;
|
| 85 |
+
padding: 1.5rem 1.8rem;
|
| 86 |
+
margin-bottom: 1.8rem;
|
| 87 |
+
box-shadow: 0 1px 3px rgba(0,0,0,0.02);
|
| 88 |
}
|
| 89 |
|
| 90 |
.card h2 {
|
| 91 |
+
font-size: 1.3rem;
|
| 92 |
font-weight: 400;
|
| 93 |
color: var(--accent);
|
|
|
|
|
|
|
| 94 |
border-bottom: 1px solid var(--border);
|
| 95 |
padding-bottom: 0.5rem;
|
| 96 |
+
margin-bottom: 1rem;
|
| 97 |
+
letter-spacing: -0.01em;
|
| 98 |
}
|
| 99 |
|
| 100 |
.card h3 {
|
| 101 |
+
font-size: 1.05rem;
|
| 102 |
font-weight: 700;
|
| 103 |
+
margin: 1.2rem 0 0.5rem;
|
| 104 |
+
color: #222;
|
| 105 |
}
|
| 106 |
|
| 107 |
+
.card p, .card li {
|
| 108 |
+
font-size: 0.9rem;
|
|
|
|
| 109 |
color: #333;
|
| 110 |
+
margin-bottom: 0.5rem;
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 111 |
}
|
| 112 |
|
| 113 |
+
/* Tables */
|
|
|
|
|
|
|
|
|
|
|
|
|
| 114 |
.table-wrap {
|
| 115 |
overflow-x: auto;
|
| 116 |
margin: 1rem 0;
|
|
|
|
| 119 |
table {
|
| 120 |
width: 100%;
|
| 121 |
border-collapse: collapse;
|
| 122 |
+
font-size: 0.85rem;
|
| 123 |
}
|
| 124 |
|
| 125 |
th {
|
| 126 |
text-align: left;
|
| 127 |
font-weight: 600;
|
| 128 |
+
font-size: 0.75rem;
|
| 129 |
+
letter-spacing: 0.05em;
|
| 130 |
text-transform: uppercase;
|
| 131 |
color: var(--muted);
|
| 132 |
+
padding: 0.55rem 0.5rem;
|
| 133 |
+
border-bottom: 2px solid var(--border);
|
| 134 |
+
background: #fafaf8;
|
| 135 |
}
|
| 136 |
|
| 137 |
td {
|
| 138 |
+
padding: 0.55rem 0.5rem;
|
| 139 |
border-bottom: 1px solid var(--border);
|
| 140 |
vertical-align: top;
|
| 141 |
}
|
| 142 |
|
| 143 |
+
tr:nth-child(even) td {
|
| 144 |
+
background: var(--row-stripe);
|
| 145 |
+
}
|
| 146 |
+
|
| 147 |
+
/* Badges */
|
| 148 |
+
.badge {
|
| 149 |
display: inline-block;
|
| 150 |
+
font-size: 0.7rem;
|
| 151 |
+
font-weight: 700;
|
|
|
|
|
|
|
| 152 |
letter-spacing: 0.04em;
|
| 153 |
+
padding: 0.2rem 0.55rem;
|
| 154 |
border-radius: 3px;
|
| 155 |
+
text-transform: uppercase;
|
| 156 |
+
white-space: nowrap;
|
| 157 |
+
}
|
| 158 |
+
.badge-novel { background: #e8e0f0; color: #4a2c6e; }
|
| 159 |
+
.badge-pending { background: var(--flag-bg); color: var(--flag-text); }
|
| 160 |
+
.badge-verified { background: var(--ok-bg); color: var(--ok-text); }
|
| 161 |
+
.badge-alert { background: var(--alert-bg); color: var(--alert-text); }
|
| 162 |
+
.badge-volume { background: var(--tag-bg); color: var(--tag-text); }
|
| 163 |
+
|
| 164 |
+
/* Lists */
|
| 165 |
+
ul.nested {
|
| 166 |
+
list-style-type: none;
|
| 167 |
+
padding-left: 0;
|
| 168 |
+
}
|
| 169 |
+
ul.nested li {
|
| 170 |
+
padding-left: 1.2rem;
|
| 171 |
+
text-indent: -1.2rem;
|
| 172 |
margin-bottom: 0.3rem;
|
| 173 |
}
|
| 174 |
+
ul.nested li::before {
|
| 175 |
+
content: "βΉ ";
|
| 176 |
+
color: var(--accent);
|
| 177 |
+
font-size: 0.8rem;
|
| 178 |
}
|
| 179 |
|
| 180 |
+
/* Timeline / Reading Path */
|
| 181 |
+
.path-box {
|
| 182 |
+
border-left: 3px solid var(--accent);
|
| 183 |
+
padding-left: 1rem;
|
| 184 |
+
margin: 0.8rem 0;
|
| 185 |
+
background: #fdfdfb;
|
| 186 |
}
|
| 187 |
|
| 188 |
+
.path-box strong {
|
|
|
|
| 189 |
color: var(--accent);
|
|
|
|
|
|
|
| 190 |
}
|
| 191 |
|
| 192 |
/* Footer */
|
| 193 |
footer {
|
| 194 |
text-align: center;
|
| 195 |
+
font-size: 0.75rem;
|
| 196 |
color: var(--muted);
|
| 197 |
margin-top: 2rem;
|
| 198 |
+
padding-top: 1.2rem;
|
| 199 |
border-top: 1px solid var(--border);
|
| 200 |
}
|
| 201 |
|
| 202 |
+
@media (max-width: 600px) {
|
| 203 |
+
body { padding: 1rem 0.3rem; }
|
| 204 |
+
h1 { font-size: 1.5rem; }
|
| 205 |
+
.card { padding: 1rem; }
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 206 |
}
|
| 207 |
</style>
|
| 208 |
</head>
|
|
|
|
| 210 |
<div class="container">
|
| 211 |
|
| 212 |
<!-- Header -->
|
| 213 |
+
<div class="doc-id">PSDLEF-TP-001-MASTER-INDEX</div>
|
| 214 |
+
<h1>MASTER INDEX β PORTFOLIO TABLE OF CONTENTS</h1>
|
| 215 |
+
<div class="subtitle">Pro Se Disability Litigant Empowerment Foundation β Technical Package</div>
|
| 216 |
+
<div class="version-line">
|
| 217 |
+
<span>Revision 2.0 • July 2026</span>
|
| 218 |
+
<span>Unified Canonical Numbering Active</span>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 219 |
</div>
|
| 220 |
|
| 221 |
+
<!-- PART A: Portfolio Overview -->
|
| 222 |
<div class="card">
|
| 223 |
+
<h2>PART A: PORTFOLIO OVERVIEW AND NAVIGATION</h2>
|
|
|
|
|
|
|
| 224 |
<div class="table-wrap">
|
| 225 |
<table>
|
| 226 |
<thead>
|
| 227 |
+
<tr><th>Vol</th><th>Title</th><th>Primary Content</th><th>Reviewer Audience</th></tr>
|
|
|
|
|
|
|
|
|
|
|
|
|
| 228 |
</thead>
|
| 229 |
<tbody>
|
| 230 |
+
<tr><td><span class="badge badge-volume">I</span></td><td>Executive Summary</td><td>Overview, Master Index, Authority Matrix</td><td>Clerks, Staff Attorneys, Initial Reviewers</td></tr>
|
| 231 |
+
<tr><td><span class="badge badge-volume">II</span></td><td>Scientific Dissertation</td><td>Peer-reviewed research, methodology, reproducibility</td><td>Scientific Experts, Amici</td></tr>
|
| 232 |
+
<tr><td><span class="badge badge-volume">III</span></td><td>Security & Zero Trust</td><td>PQC Architecture, Secure Enclave, Merkle DAG Ledger</td><td>CISOs, Security Auditors</td></tr>
|
| 233 |
+
<tr><td><span class="badge badge-volume">IV</span></td><td>Software Architecture</td><td>R Package Architecture, COBOL Controller, REST API</td><td>Technical Experts, IT Specialists</td></tr>
|
| 234 |
+
<tr><td><span class="badge badge-volume">V</span></td><td>Regulatory</td><td>FDA Software Lifecycle, Design Controls, Traceability</td><td>FDA Reviewers, QMS Auditors</td></tr>
|
| 235 |
+
<tr><td><span class="badge badge-volume">VI</span></td><td>Artificial Intelligence</td><td>Scientific Assimilation Engine, XAI, Hallucination Detection</td><td>ML Engineers, Ethics Boards</td></tr>
|
| 236 |
+
<tr><td><span class="badge badge-volume">VII</span></td><td>Reproducibility</td><td>Docker/Nix Builds, Provenance Ledger, FAIR Metadata</td><td>Bioinformaticians, Auditors</td></tr>
|
| 237 |
+
<tr><td><span class="badge badge-volume">VIII</span></td><td>Litigation & Evidence</td><td>Evidence Chain, Exhibit Generation, Expert Witness Workflow</td><td>Court, Opposing Counsel</td></tr>
|
| 238 |
+
<tr><td><span class="badge badge-volume">IX</span></td><td>End-to-End Genomic Pipeline</td><td>23andMe β PRS Engine β Secure Evidence Ledger</td><td>Pipeline Developers, Clinicians</td></tr>
|
| 239 |
+
<tr><td><span class="badge badge-volume">X</span></td><td>Reference Materials</td><td>Master Bibliography, Acronym Index, Glossary</td><td>All Reviewers</td></tr>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 240 |
</tbody>
|
| 241 |
</table>
|
| 242 |
</div>
|
| 243 |
+
<p style="margin-top:0.5rem;"><em>All volumes use unified canonical identifiers. FIG. 14, TABLE 17, ALG. 4, MOD. 8, PAT. FIG. 14, FDA V&V-14, and EXH. 14 all trace to the same PRS computation concept.</em></p>
|
|
|
|
|
|
|
| 244 |
</div>
|
| 245 |
|
| 246 |
+
<!-- PART B: Volume I TOC -->
|
| 247 |
<div class="card">
|
| 248 |
+
<h2>PART B: VOLUME I β TABLE OF CONTENTS</h2>
|
| 249 |
+
|
| 250 |
+
<h3>Front Matter</h3>
|
| 251 |
+
<ul class="nested">
|
| 252 |
+
<li>FM-1. Title Page and Portfolio Identifier</li>
|
| 253 |
+
<li>FM-2. Certification of Authenticity and Integrity</li>
|
| 254 |
+
<li>FM-3. Confidentiality Designation and Redaction Index</li>
|
| 255 |
+
<li>FM-4. Master Authority Matrix (CP, SG, DA, SR, LF Domains)</li>
|
| 256 |
+
<li>FM-5. Document Control and Version History</li>
|
| 257 |
+
<li>FM-6. List of Contributing Authors and Affiliations</li>
|
| 258 |
+
<li>FM-7. Correspondence and Service List</li>
|
| 259 |
+
</ul>
|
| 260 |
|
| 261 |
+
<h3>Chapter 1: Portfolio Summary and Core Propositions</h3>
|
| 262 |
+
<ul class="nested">
|
| 263 |
+
<li>1.1. Executive Summary of the Scientific Dissertation (Cross-Ref: Vol. II, Ch. 1β4)</li>
|
| 264 |
+
<li>1.2. Summary of Patent Portfolio and Invention Families (Cross-Ref: Vol. III, Spec. 1βN)</li>
|
| 265 |
+
<li>1.3. Overview of Proposed Legal Theories (Cross-Ref: Vol. V, Ch. 2β5)
|
| 266 |
+
<ul class="nested">
|
| 267 |
+
<li>1.3.1. Genomic Information as Property Under Takings Clause <span class="badge badge-novel">Novel Theory</span></li>
|
| 268 |
+
<li>1.3.2. Due Process Implications of AI Accommodation Refusal <span class="badge badge-novel">Novel Theory</span></li>
|
| 269 |
+
<li>1.3.3. SSA Obligation to Accept AI-Based Accommodation <span class="badge badge-novel">Novel Theory</span></li>
|
| 270 |
+
<li>1.3.4. USCIT Jurisdiction Over Post-Quantum Hardware and International Standards Claims <span class="badge badge-novel">Novel Theory</span></li>
|
| 271 |
+
</ul>
|
| 272 |
+
</li>
|
| 273 |
+
<li>1.4. Administrative and Regulatory Context (Cross-Ref: Vol. VI, Regulatory)</li>
|
| 274 |
+
<li>1.5. International Human Rights Framework (Cross-Ref: Vol. IX, Policy Materials)</li>
|
| 275 |
+
</ul>
|
| 276 |
|
| 277 |
+
<h3>Chapter 2: Master Cross-Reference Index</h3>
|
| 278 |
+
<ul class="nested">
|
| 279 |
+
<li>2.1. Exhibit Master List (All Volumes)
|
| 280 |
+
<ul class="nested">
|
| 281 |
+
<li>2.1.1. Scientific Exhibits (P-1 through P-NN) [Cross-Ref: Vol. VIII, Scientific Exhibits]</li>
|
| 282 |
+
<li>2.1.2. Legal Exhibits (L-1 through L-NN) [Cross-Ref: Vol. V, App.]</li>
|
| 283 |
+
<li>2.1.3. Administrative Exhibits (A-1 through A-NN) [Cross-Ref: Vol. VI, Admin Record]</li>
|
| 284 |
+
<li>2.1.4. Technical Exhibits (T-1 through T-NN) [Cross-Ref: Vol. IV, Software App.]</li>
|
| 285 |
+
</ul>
|
| 286 |
+
</li>
|
| 287 |
+
<li>2.2. Figure Index (Unified Canonical, Cross-Ref: Vol. X)</li>
|
| 288 |
+
<li>2.3. Table Index (Unified Canonical, Cross-Ref: Vol. X)</li>
|
| 289 |
+
<li>2.4. Algorithm and Code Appendix Index (Cross-Ref: Vol. IV, App. C; Vol. VII, Reproducibility)</li>
|
| 290 |
+
<li>2.5. Authority Identifier Concordance (CP, SG, DA, SR, LF)</li>
|
| 291 |
+
</ul>
|
| 292 |
|
| 293 |
+
<h3>Chapter 3: Statistical Claims Verification and Qualification</h3>
|
| 294 |
+
<ul class="nested">
|
| 295 |
+
<li>3.1. Inventory of All Numerical Claims Across Portfolio</li>
|
| 296 |
+
<li>3.2. Status of Supporting Sources
|
| 297 |
+
<ul class="nested">
|
| 298 |
+
<li>3.2.1. Claims with Verified Sources <span class="badge badge-verified">Verified</span></li>
|
| 299 |
+
<li>3.2.2. Claims Requiring Additional Support <span class="badge badge-pending">Flagged</span></li>
|
| 300 |
+
<li>3.2.3. Claims Removed Pending Verification <span class="badge badge-alert">Quarantined</span></li>
|
| 301 |
+
</ul>
|
| 302 |
+
</li>
|
| 303 |
+
<li>3.3. Specific Qualifications:
|
| 304 |
+
<ul class="nested">
|
| 305 |
+
<li>3.3.1. "40% Unaccommodated Error Rate" β <span class="badge badge-pending">Under Review; Source Pending</span></li>
|
| 306 |
+
<li>3.3.2. "1.15 Million Americans" β <span class="badge badge-pending">Under Review; Source Pending</span></li>
|
| 307 |
+
<li>3.3.3. "60% Increase" β <span class="badge badge-pending">Under Review; Source Pending</span></li>
|
| 308 |
+
<li>3.3.4. "30,000 Annual Deaths" β <span class="badge badge-pending">Under Review; Source Pending</span></li>
|
| 309 |
+
</ul>
|
| 310 |
+
</li>
|
| 311 |
+
<li>3.4. Methodology for Statistical Validation (Cross-Ref: Vol. II, Statistical Analysis Plan)</li>
|
| 312 |
+
</ul>
|
| 313 |
|
| 314 |
+
<h3>Chapter 4: Terminology and Definitions</h3>
|
| 315 |
+
<ul class="nested">
|
| 316 |
+
<li>4.1. Glossary of Technical Terms (Cross-Ref: Vol. X, Glossary)</li>
|
| 317 |
+
<li>4.2. Acronym Index (Cross-Ref: Vol. X, Acronym Index)</li>
|
| 318 |
+
<li>4.3. Defined Legal Terms and Proposed Theories</li>
|
| 319 |
+
<li>4.4. "Phantom Variant OCR Pipelines" β <span class="badge badge-pending">Definition Pending</span>
|
| 320 |
+
<ul class="nested">
|
| 321 |
+
<li>4.4.1. Proposed Definition (Pending)</li>
|
| 322 |
+
<li>4.4.2. Supporting Technical Evidence (Cross-Ref: Vol. IV, App. D)</li>
|
| 323 |
+
<li>4.4.3. Alternative: Removal and Substitution with Concrete Description</li>
|
| 324 |
+
</ul>
|
| 325 |
+
</li>
|
| 326 |
+
<li>4.5. "Supported Workflow Components" β Clarification: Established tools (BWA, minimap2, GATK, DeepVariant) described as integrated workflow stages orchestrated by an R-based layer; not reimplemented in pure R. (Cross-Ref: Vol. IV, Software Architecture; Vol. VII, Reproducibility)</li>
|
| 327 |
+
</ul>
|
| 328 |
+
|
| 329 |
+
<h3>Chapter 5: Filing Compliance and Procedural Verification</h3>
|
| 330 |
+
<ul class="nested">
|
| 331 |
+
<li>5.1. Applicable Filing Rules and Jurisdictional Requirements
|
| 332 |
+
<ul class="nested">
|
| 333 |
+
<li>5.1.1. SCOTUS Rule 33.1 β <span class="badge badge-pending">Jurisdiction and Document Type Under Verification</span></li>
|
| 334 |
+
<li>5.1.2. Lower Court Filing Requirements (If Applicable)</li>
|
| 335 |
+
<li>5.1.3. Administrative Filing Requirements</li>
|
| 336 |
+
</ul>
|
| 337 |
+
</li>
|
| 338 |
+
<li>5.2. Word Count and Formatting Verification Log</li>
|
| 339 |
+
<li>5.3. Word-Limit Compliance Statement (Pending Independent Verification)</li>
|
| 340 |
+
</ul>
|
| 341 |
+
|
| 342 |
+
<h3>Chapter 6: Reading Guide by Reviewer Type</h3>
|
| 343 |
+
<div class="path-box"><strong>Judicial Clerks & Staff Attorneys:</strong> Vols. I β V β VI β VII (Litigation & Administrative Record)</div>
|
| 344 |
+
<div class="path-box"><strong>Scientific Experts & Amici:</strong> Vols. I β II β VIII β IV (Dissertation, Exhibits, Software)</div>
|
| 345 |
+
<div class="path-box"><strong>Technical/IT Reviewers:</strong> Vols. I β IV β VII β III (Software, Reproducibility, Security)</div>
|
| 346 |
+
<div class="path-box"><strong>FDA/Regulatory Reviewers:</strong> Vols. I β V β IV β VII (Regulatory, Software, Reproducibility)</div>
|
| 347 |
+
<div class="path-box"><strong>International Bodies:</strong> Vols. I β IX β II β VIII (Human Rights, Dissertation, Exhibits)</div>
|
| 348 |
+
<div class="path-box"><strong>Patent Examiners & Licensing Counsel:</strong> Vols. I β III (Patent Specs) β IV (Software) β VII (Reproducibility)</div>
|
| 349 |
+
|
| 350 |
+
<h3>Back Matter</h3>
|
| 351 |
+
<ul class="nested">
|
| 352 |
+
<li>BM-1. Master Bibliography by Subject (Abbreviated; Full: Vol. X)</li>
|
| 353 |
+
<li>BM-2. Document Production Log</li>
|
| 354 |
+
<li>BM-3. Errata and Revision Tracking</li>
|
| 355 |
+
<li>BM-4. Contact Information for Portfolio Administrator</li>
|
| 356 |
</ul>
|
| 357 |
</div>
|
| 358 |
|
| 359 |
+
<!-- PART C: Quick-Reference Cross-Walk -->
|
| 360 |
<div class="card">
|
| 361 |
+
<h2>PART C: QUICK-REFERENCE CROSS-WALK</h2>
|
| 362 |
+
<div class="table-wrap">
|
| 363 |
+
<table>
|
| 364 |
+
<thead>
|
| 365 |
+
<tr><th>Claim / Term</th><th>Location in Portfolio</th><th>Status</th><th>Authority ID</th></tr>
|
| 366 |
+
</thead>
|
| 367 |
+
<tbody>
|
| 368 |
+
<tr><td>Genomic info = property (Takings)</td><td>Vol. V, Ch. 3; Vol. I, Β§1.3.1</td><td><span class="badge badge-novel">Proposed Theory</span></td><td>[CP-___]</td></tr>
|
| 369 |
+
<tr><td>AI refusal = due process violation</td><td>Vol. V, Ch. 3; Vol. I, Β§1.3.2</td><td><span class="badge badge-novel">Proposed Theory</span></td><td>[DA-___]</td></tr>
|
| 370 |
+
<tr><td>SSA must accept AI accommodation</td><td>Vol. V, Ch. 4; Vol. I, Β§1.3.3</td><td><span class="badge badge-novel">Proposed Theory</span></td><td>[SG-___]</td></tr>
|
| 371 |
+
<tr><td>USCIT jurisdiction (post-quantum)</td><td>Vol. V, Ch. 5; Vol. I, Β§1.3.4</td><td><span class="badge badge-novel">Proposed Theory</span></td><td>[LF-___]</td></tr>
|
| 372 |
+
<tr><td>40% unaccommodated error rate</td><td>Vol. V, App.; Vol. I, Β§3.3.1</td><td><span class="badge badge-pending">Source Pending</span></td><td>[SR-___]</td></tr>
|
| 373 |
+
<tr><td>1.15 million Americans</td><td>Vol. V, App.; Vol. I, Β§3.3.2</td><td><span class="badge badge-pending">Source Pending</span></td><td>[SR-___]</td></tr>
|
| 374 |
+
<tr><td>60% increase</td><td>Vol. V, App.; Vol. I, Β§3.3.3</td><td><span class="badge badge-pending">Source Pending</span></td><td>[SR-___]</td></tr>
|
| 375 |
+
<tr><td>30,000 annual deaths</td><td>Vol. V, App.; Vol. I, Β§3.3.4</td><td><span class="badge badge-pending">Source Pending</span></td><td>[SR-___]</td></tr>
|
| 376 |
+
<tr><td>Phantom variant OCR pipelines</td><td>Vol. IV, App. D; Vol. I, Β§4.4</td><td><span class="badge badge-pending">Definition Pending</span></td><td>[CP-___]</td></tr>
|
| 377 |
+
<tr><td>BWA/minimap2/GATK as supported workflow</td><td>Vol. IV, App. C; Vol. I, Β§4.5</td><td><span class="badge badge-verified">Clarified</span></td><td>[SR-___]</td></tr>
|
| 378 |
+
<tr><td>PRS Workflow (Unified FIG. 14)</td><td>Vol. II, IX; PAT. FIG. 14; EXH. 14</td><td><span class="badge badge-verified">Canonical</span></td><td>[SG-___]</td></tr>
|
| 379 |
+
<tr><td>ML-KEM / ML-DSA / SLH-DSA Registry</td><td>Vol. III, Tables 1β6</td><td><span class="badge badge-verified">Documented</span></td><td>[DA-___]</td></tr>
|
| 380 |
+
<tr><td>FDA Traceability Matrix</td><td>Vol. V, Table 5; FDA V&V-14</td><td><span class="badge badge-verified">Mapped</span></td><td>[LF-___]</td></tr>
|
| 381 |
+
</tbody>
|
| 382 |
+
</table>
|
| 383 |
</div>
|
| 384 |
</div>
|
| 385 |
|
| 386 |
<!-- Footer -->
|
| 387 |
<footer>
|
| 388 |
+
<em>Prepared in accordance with the Master Authority Matrix. Every substantive proposition cross-references its controlling Authority Identifier. Unverified claims are flagged and quarantined pending source confirmation. Established bioinformatics tools are documented as supported workflow components orchestrated by an R-based layer.</em>
|
| 389 |
<br><br>
|
| 390 |
+
© 2026 Pro Se Disability Litigant Empowerment Foundation β Technical Package, Volume I
|
| 391 |
</footer>
|
| 392 |
|
| 393 |
</div>
|